Interim Efficacy Analysis, Follow-up Milestone Period

No definition available.

Name:	clbs_InterimEfficacyAnalysisFollowupMilestonePeriod
Namespace Prefix:	clbs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Interim Efficacy Analysis, Percentage Threshold

+ References

No definition available.

+ Details

Name:	clbs_InterimEfficacyAnalysisPercentageThreshold
Namespace Prefix:	clbs_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Patients Enrolled

+ References

No definition available.

+ Details

Name:	clbs_NumberOfPatientsEnrolled
Namespace Prefix:	clbs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Cohorts

+ References

No definition available.

+ Details

Name:	clbs_NumberofCohorts
Namespace Prefix:	clbs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RevenueFromGrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_IschemicRepairCD34CellTechnologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_TheSanfordProjectTRexStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Business - Narrative (Details) $ in Millions	1 Months Ended					3 Months Ended	6 Months Ended
The Business - Narrative (Details) $ in Millions	Mar. 31, 2018 USD ($)	Jan. 31, 2018 patient	Dec. 31, 2017 USD ($)	Oct. 31, 2017 USD ($)	Oct. 31, 2016 patient	Mar. 31, 2016 cohort	Jun. 30, 2018 USD ($)	Feb. 28, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants	$ 0.3		$ 1.9				$ 7.9
Grants receivable	$ 8.6							$ 12.2
Ischemic Repair (CD34 Cell Technology) [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants				$ 1.9
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of cohorts \| cohort						2
Number of patients enrolled \| patient		110			19
Interim efficacy analysis, threshold (percent)					50.00%
Interim efficacy analysis, follow-up milestone period					6 months